![comprehensive meta analysis auroc comprehensive meta analysis auroc](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/3efed8be-2464-4d0c-8c5a-947b71d3264f/gr1_lrg.jpg)
The current protocolized treatment for high grade glioma is surgery followed by concurrent radiotherapy and temozolomide chemotherapy despite this, glioma remains a highly aggressive cancer with extremely poor prognosis, resulting in median survival of less than 15 months. Glioma is categorized according to the World Health Organization (WHO) grading system, grade I and II are classified as benign and low grade glioma while grade III and IV are high grade glioma. The incidence of glioma in adults varies from 1.32 to 5.73 per 100, 000 person, depending on geographic location.
![comprehensive meta analysis auroc comprehensive meta analysis auroc](https://bermoaqua.weebly.com/uploads/1/2/7/5/127504730/662314856.png)
Glioma, the most prevalent malignant cancer in the central nervous system, has a content of latent progression before histopathological diagnosis. įunding: We would like to acknowledge the Cure Brain Cancer Foundation, the Royal Melbourne Hospital Neuroscience Foundation for their funding support to Dr A.Morokoff and Melbourne International Research Scholarship to Mr C.Ma, and the Victorian Government for Infrastructure support.Ĭompeting interests: The authors have declared that no competing interests exist. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.ĭata Availability: All figures files are available from the figshare database. Received: AugAccepted: NovemPublished: February 14, 2018Ĭopyright: © 2018 Ma et al. PLoS ONE 13(2):Įditor: Bing-Hua Jiang, Thomas Jefferson University, UNITED STATES (2018) A comprehensive meta-analysis of circulation miRNAs in glioma as potential diagnostic biomarker.
![comprehensive meta analysis auroc comprehensive meta analysis auroc](http://www.sciencesoftware.com.cn/admin/upload/soft/201441553451497.jpg)
Circulating miRNAs are promising diagnostic biomarkers for glioma and can potentially be used as a non-invasive early detection.Ĭitation: Ma C, Nguyen HPT, Luwor RB, Stylli SS, Gogos A, Paradiso L, et al. This meta-analysis demonstrated that circulating miRNAs are capable of distinguishing glioma from healthy controls. The pooled sensitivity, specificity, positive likelihood ratio (PLR) and negative likelihood ratio (NLR) from each study were calculated. The pooled diagnostic parameters were calculated by random effect models and overall diagnostic performance of altered miRNAs was illustrated by the summary receiver operator characteristic (SROC) curves. Sixteen publications involving 23 studies of miRNAs from serum or plasma met our criteria and were included in this meta-analysis. Using PubMed, Medline and Cochrane databases, we searched for studies which evaluated a single or panel of miRNAs from circulating blood as potential biomarkers of glioma. Here we performed a meta-analysis to identify the diagnostic accuracy of differentially expressed circulating miRNAs in gliomas. Recently, several publications have suggested that miRNAs can be used as potential diagnostic biomarkers of glioma. Glioma is the most common malignant intracranial tumour.